Ivarmacitinib (SHR0302) sulfate, a potent and orally active inhibitor of all JAK family members, exhibits particular selectivity towards JAK1. Its selectivity is >10-fold greater for JAK1 compared to JAK2, 77-fold more than JAK3, and 420-fold more than Tyk2. Ivarmacitinib effectively inhibits JAK1-STAT3 phosphorylation, thereby inducing apoptosis in hepatic stellate cells. Additionally, it demonstrates notable anti-proliferative and anti-inflammatory properties [1] [2].